VTGN NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

VistaGen Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 0.24 USD
6.4% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -55.7% below the Trend Line and sits at 0.9% of its 52-week range. The latest completed week returned 6.4%, after a -3.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 66/100 conviction, while the latest news-sentiment score is 44/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 20 out of 100
Latest Close 0.24 USD 31 Jul 2026
1W Return 6.4% latest completed week
4W Return -3.2% short-term follow-through
12W Return -60.5% quarterly tape
Trend Breadth 32.7% 17 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 6.4% Latest completed week; four-week move -3.2%. Indicator stack 18/37 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 66/100 conviction; expected move 46.6%. News sentiment 44/100 59 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -55.7% below the Trend Line and sits at 0.9% of its 52-week range. The latest completed week returned 6.4%, after a -3.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1412-week average 0.21

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure10/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.14Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.2% over four weeks, -60.5% over 12 weeks, and -91.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W6.4%
4W-3.2%
12W-60.5%
26W-56.8%
52W-91.7%
Active trend streak0 weeks
Active weeks in one year17
Trend breadth32.7%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.19Latest activity-pressure read.
Pressure change-124.4%Four-week change in activity pressure.
Leadership-87.78Latest relative-leadership reading.
RS change1.5%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength30/100Blend of value, momentum, and quality. Underlying universe rank 71; rank 1 is best.
Value41/100Relative valuation strength. Underlying universe rank 60; rank 1 is best.
Quality40/100Profitability and accounting quality. Underlying universe rank 61; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth41/100Revenue and earnings growth. Underlying universe rank 60; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
71.8%
Gross profit retained from each unit of revenue.
Operating margin
-5521.9%
Operating profit retained from revenue.
Free-cash-flow margin
-5206.8%
Free cash flow generated from revenue.
Return on invested capital
-910.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
161.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

VTGN shows volatility options pressure with a 66/100 conviction score, put-call volume ratio of 8.62, expected move of 46.6%, and Sharemaestro trend signal inactive.

Conviction66/100
Expected move46.6%
Put/call volume8.62
Pressure-68
Speculation16
Volatility96
Trend agreement94
Open options detail
Insider activity4 / 0

4 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment44/100

Weighted news tone is neutral across 59 relevant articles.

5 positive · 38 neutral · 16 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move46.6%Nearest-chain priced movement where available.
52-week drawdown-95.3%Distance below the 52-week high.
13-week volatility19.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+16.3%Week of 19 Jun.
Worst week-64.5%Week of 3 Jul.
Latest week+6.4%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains7
Flat weeks0
Modest losses4
Sharp losses7
Recent vol19.0%13-week weekly-return volatility.
Base vol16.2%52-week weekly-return volatility.
Up/down split28/24Count of positive and negative weeks in the 52-week window.
Average skew6.1% / -11.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape23/100

Trend, activity pressure, participation, and risk combine to a 23/100 tape read.

 Indicator analysis28/100

Latest 12-week confirmation: trend 0/12, activity pressure 10/12, relative leadership 0/12.

Activity pressure 0.14; No reversal markers Factors37/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options66/100

VTGN shows volatility options pressure with a 66/100 conviction score, put-call volume ratio of 8.62, expected move of 46.6%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 46.6% Sentiment44/100

Weighted news tone is neutral across 59 relevant articles.

Form 4 VistaGen Therapeutics Inc For: 31 July By Investing.com Insiders4 / 0

4 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20260.24 USD6.4%0.54 USD2.98 USD-0.19-87.784.9MOff
24 Jul 20260.23 USD-1.2%0.56 USD2.98 USD-0.08-88.823.7MOff
17 Jul 20260.23 USD-11.2%0.58 USD3.00 USD0.30-89.234.4MOff
10 Jul 20260.26 USD3.7%0.59 USD3.01 USD0.67-88.6811.5MOff
3 Jul 20260.25 USD-64.5%0.73 USD3.02 USD0.77-89.1463.6MOff
26 Jun 20260.70 USD4.7%0.86 USD3.03 USD0.79-69.705.2MOff
19 Jun 20260.67 USD16.3%1.00 USD3.03 USD0.58-72.798.6MOff
12 Jun 20260.58 USD5.9%1.13 USD3.04 USD0.38-76.383.1MOff
5 Jun 20260.54 USD-13.7%1.24 USD3.05 USD0.51-77.623.7MOff
29 May 20260.63 USD-2.6%1.36 USD3.06 USD0.55-75.752.0MOff
22 May 20260.65 USD3.5%1.47 USD3.08 USD0.52-74.942.6MOff
15 May 20260.62 USD2.4%1.58 USD3.10 USD0.55-76.009.8MOff
8 May 20260.61 USD-2.4%1.69 USD3.12 USD0.48-77.092.6MOff
1 May 20260.63 USD5.4%1.81 USD3.15 USD0.39-75.691.9MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.